Les traitements anticoagulants oraux chez les personnes âgées : faut-il encore prescrire des antivitamines K ?

Agence National de Sécurité du Médicament et des produits de santé (ANSM), 2014 Salem, 2015, Pharmacology and mechanisms of action of new oral anticoagulants, Fundam Clin Pharmacol, 29, 10, 10.1111/fcp.12091 Steffel, 2018, The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, 39, 1330, 10.1093/eurheartj/ehy136 Siguret, 2005, Initiation of warfarin in elderly medical inpatients: a safe and accurate regimen, Am J Med, 118, 137, 10.1016/j.amjmed.2004.07.053 Gouin-Thibault, 2010, Improving anticoagulation control in hospitalized elderly patients on warfarin, J Am Geriatr Soc, 58, 242, 10.1111/j.1532-5415.2009.02675.x Hylek, 2007, Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation, Circulation, 115, 2689, 10.1161/CIRCULATIONAHA.106.653048 Mavrakanas, 2011, The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism, Pharmacol Ther, 130, 46, 10.1016/j.pharmthera.2010.12.007 van Ryn, 2010, Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost, 103, 1116, 10.1160/TH09-11-0758 Stangier, 2008, Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects, Clin Pharmacokinet, 47, 47, 10.2165/00003088-200847010-00005 Frost, 2009, Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban (abstract PP-MO-407), J Thromb Haemost, 7, 455 Kubitza, 2006, The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban: an oral, direct factor Xa inhibitor [abstract no 905], Blood, 108, 905, 10.1182/blood.V108.11.905.905 Mueck, 2011, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention, Clin Pharmacokinet, 50, 675, 10.2165/11595320-000000000-00000 Tornkvist, 2018, Current evidence of oral anticoagulant reversal: a systematic review, Thromb Res, 162, 22, 10.1016/j.thromres.2017.12.003 RE-LY Steering Committee and Investigators, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 ROCKET AF Investigators, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 ARISTOTLE Committees and Investigators, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Eikelboom, 2011, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, Circulation, 123, 2363, 10.1161/CIRCULATIONAHA.110.004747 Gomez-Outes, 2016, Causes of death in anticoagulated patients with atrial fibrillation, J Am Coll Cardiol, 68, 2508, 10.1016/j.jacc.2016.09.944 Bruins Slot, 2018, Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation, Cochrane Database Syst Rev, 3, CD008980 Sardar, 2014, New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials, J Am Geriatr Soc, 62, 857, 10.1111/jgs.12799 Sharma, 2015, Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis, Circulation, 132, 194, 10.1161/CIRCULATIONAHA.114.013267 Haute Autorité de Santé (HAS). Fiches de bon usage du médicament : les anticoagulants oraux. Accessible (septembre 2018) sur : https://www.has-sante.fr/portail/jcms/c_2851086/fr/les-anticoagulants-oraux. Kirchhof, 2016, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, 37, 2893, 10.1093/eurheartj/ehw210 RE-COVER Study Group, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 Büller, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 Gibson, 2016, Prevention of bleeding in patients with atrial fibrillation undergoing PCI, N Engl J Med, 375, 2423, 10.1056/NEJMoa1611594 Cannon, 2017, Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation, N Engl J Med, 377, 1513, 10.1056/NEJMoa1708454 Dewilde, 2013, Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet, 381, 1107, 10.1016/S0140-6736(12)62177-1 Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 Eikelboom, 2017, Rivaroxaban with or without aspirin in stable cardiovascular disease, N Engl J Med, 377, 1319, 10.1056/NEJMoa1709118 Alexander, 2011, Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med, 365, 699, 10.1056/NEJMoa1105819 Eikelboom JW1, 2013, Dabigatran versus warfarin in patients with mechanical heart valves, N Engl J Med, 369, 1206, 10.1056/NEJMoa1300615 Ntaios, 2017, Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis, Stroke, 48, 2494, 10.1161/STROKEAHA.117.017549 Chao, 2018, Oral anticoagulation in very elderly patients with atrial fibrillation – a nationwide cohort study, Circulation, 10.1161/CIRCULATIONAHA.117.031658 Becattini, 2018, Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation, J Thromb Haemost, 16, 833, 10.1111/jth.13985 Kimachi, 2017, Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease, Cochrane Database Syst Rev, 11, CD011373 Chan, 2016, Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF, J Am Coll Cardiol, 67, 2888, 10.1016/j.jacc.2016.02.082 Froom, 2003, Oral anticoagulants in the elderly, Br J Haematol, 120, 526, 10.1046/j.1365-2141.2003.04110.x Gurwitz, 2007, The safety of warfarin therapy in the nursing home setting, Am J Med, 120, 539, 10.1016/j.amjmed.2006.07.045 Reilly, 2014, The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial, J Am Coll Cardiol, 63, 321, 10.1016/j.jacc.2013.07.104 Cohen, 2014, Dabigatran: how the drug company withheld important analyses, BMJ, 349, g4670, 10.1136/bmj.g4670 Abraham, 2015, Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study, BMJ, 350, h1857, 10.1136/bmj.h1857 Apostolakis, 2012, Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS study, J Am Coll Cardiol, 60, 861, 10.1016/j.jacc.2012.06.019 Jaspers Focks, 2016, Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists, J Thromb Haemost, 14, 1715, 10.1111/jth.13361 Hijazi, 2016, The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation, Eur Heart J, 37, 1582, 10.1093/eurheartj/ehw054 Warkentin, 2012, Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis, J Thromb Haemost, 10, 512, 10.1111/j.1538-7836.2012.04635.x Melkonian, 2017, Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis, J Thromb Haemost, 15, 1500, 10.1111/jth.13697 Connolly, 2011, Apixaban in patients with atrial fibrillation, N Engl J Med, 364, 806, 10.1056/NEJMoa1007432 Averlant, 2017, Underuse of oral anticoagulants and inappropriate prescription of antiplatelet therapy in older inpatients with atrial fibrillation, Drugs Aging, 34, 701, 10.1007/s40266-017-0477-3 Kagansky, 2004, Safety of anticoagulation therapy in well informed older patients, Arch Intern Med, 164, 2044, 10.1001/archinte.164.18.2044 Poli, 2011, Bleeding risk in very old patients on vitamin K antagonist treatment, Circulation, 124, 824, 10.1161/CIRCULATIONAHA.110.007864